Once niche, the field of neuromodulation is now accelerating toward real-world breakthroughs for conditions such as tinnitus, substance use disorder, Parkinson’s disease and epilepsy.
According to a report by GlobalData, the global neurological devices market will reach a valuation of $20.9bn by 2033, up from $12.5bn in 2023.
Go deeper with GlobalData
At Biomed Israel 2025: the 23rd National Life Science & Technology Week, taking place in Tel Aviv between 20 and 22 May, Serendipity Impact VC co-founder and managing partner Avi Yaron will give a keynote during a session titled ‘Rewiring the Brain: Breakthroughs in Neurotech and Neuromodulation’.
Moderated by Barry Greene, CEO of Sage Therapeutics; and Iris Grossman, chief therapeutics officer at Eleven Therapeutics, the session will also feature a keynote from Tanya Fischer, chief medical officer at Tenvie Therapeutics and presentations from companies such as NeuroSense Therapeutics and BrainValue NeuroTech.
Diagnosed with a brain tumour at the age of 26, Yaron embarked on a self-advocacy quest to bring into being the neurotech required to help save his life – a story he shared in a TEDx talk in 2015.
Yaron’s investment fund’s rationale is to invest in early technologies to transform mental and neuro health, with his personal journey having led him to the belief that in keeping people healthy, the future of medicine will be driven by personalised, predictive, preventative systems in which neuromodulation devices have a critical role to play.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataMedical Device Network sat down with Yaron to gain more insight into the value in neuromodulation and what the future holds for treating a range of neurological conditions.
Ross Law (RL): Aside from your personal experience with a neurological condition, why do you view neuromodulation as the future in treating neurological conditions?
Avi Yaron (AY): Let’s say that I have a headache. While I can take a pill to no longer ‘feel’ the headache, the headache is still there. The pharmacological element just shuts down the neurotransmitter so I won’t feel it, but the pain is still there; and once I stop taking the pill, the headache and the pain being felt, may return. Unlike pharma, advanced neuromodulation technologies have the potential, either to completely cure or at least allow a person to reach a state of remission.
Many neurodegenerative conditions, from depression and anxiety to Parkinson’s and Alzheimer’s disease, take over the person. Their life is no longer their life, but the life of their disease. By using neuromodulation to address their conditions, they are given back their lives and don’t face the potential of being reliant on drugs for the rest of their lives as a means of eliminating their symptoms.
I’m not against drugs. For certain conditions that we still don’t fully understand, like schizophrenia, pharmaceuticals allow individuals to lead a normal life. Rather, I’m for people having the potential to take advantage of the new developments gradually moving towards becoming a reality, as an alternative to pharmaceuticals.
As with most things, an evolution is assisted by many small revolutions. Neuromodulation has been an option for at least 30 years, but it is nowadays becoming a lot more advanced. If you look at Responsive Neurostimulation (RNS), for instance, it is possible to effectively eliminate epileptic seizures before they occur. With Parkinson’s, neuromodulation approaches can delay its onset. In my view, this is just the beginning of the evolution being seen in this field. I am genuinely convinced that neuromodulation represents the next frontier of medicine.
RL: What other advantages do technological advances in neuromodulation hold?
AY: Today, more people are developing more diseases at a younger age. I believe that it’s always good to have a plethora of potential treatments, so a physician can decide on the most appropriate approach to an individual’s needs. On the acute side, it may be best to use pharmacology, but on the chronic side, where pharma typically fails, technology can be used instead.
In turn, the rise of other technologies such as AI allows for the ability to more easily crunch big data and bring greater personalisation to patients with neurological conditions. It makes no sense that males and females, youngsters and elders, or those with dark or light skin, receive the same treatment approach to their neurological condition. There is no one-size-fits-all.
With neuro technology such as closed-loop neuromodulation, a technique that monitors brain activity or physiological signals and dynamically adjusts brain stimulation parameters in real-time, more personalised treatment modalities can be determined. And with the ability of such technologies to gather more information, in sync with AI, this not only empowers the patient, but it can also help direct them to the right treatment and the right physician.
RL: Speak about some of the companies Serendipity Impact VC has invested in.
AY: One of the companies that Serendipity has invested in enables minimally invasive approaches to treat forms of epilepsy that were considered untreatable before. This example provides an integrative use of various technologies that serve medicine and serve mankind to make treatment better, more accurate, more personalised, less invasive and less traumatic. In turn, with what will hopefully be a wider availability of technologies like this in future, I believe that, knowing these non-invasive approaches are available, that people who were afraid of treatment before would now go and get diagnosed and therefore receive treatment earlier. In time, developments of this sort will hopefully not only reduce costs to healthcare systems but also help reduce individual suffering.
RL: How is the Israeli neuromodulation ecosystem positioned to continue evolving?
AY: Startups here are leaner and often take less time and money to reach a certain result compared to those in other regions. I think that another huge advantage of Israeli startups is that they have to go global from day one. In my view, this outward-looking perspective is allowing the Israeli ecosystem to flourish in the field of neuromodulation.
